

ABSTRACT OF THE DISCLOSURE

Anti-hepatitis B virus compounds (-)3'-thia-2',3'-dideoxycytidine, (-)5-fluoro-3'-thia-2',3'-dideoxycytidine, (±) β-dioxolane cytosine and (-)-L-β-dioxolane cytosine. A method of treating a patient suffering from hepatitis B virus or preventing hepatitis B virus infection comprising administering to the patient an effective amount of an active compound selected from the group consisting of (a) (-)3'-thia-2',3'-dideoxycytidine, (b) (±)3'-thia-2'3'-dideoxycytidine, (c) (-)5-fluoro-3'-thia-2',3'-dideoxycytidine; (d) (±) 5-fluoro-3'-thia-2'3'-dideoxycytidine, (e) (±) β-dioxolane-cytosine and (f) (-)-L-β-dioxolane cytosine, or a salt or an ester thereof, either alone or in admixture within a diluent.